EMEA-002978-PIP01-21
Key facts
| Invented name |
Enhertu
|
| Active substance |
trastuzumab deruxtecan
|
| Therapeutic area |
Oncology
|
| Decision number |
P/0275/2021
|
| PIP number |
EMEA-002978-PIP01-21
|
| Pharmaceutical form(s) |
All pharmaceutical forms
|
| Condition(s) / indication(s) |
Treatment of lung cancer
|
| Route(s) of administration |
All routes of administration
|
| Contact for public enquiries |
Daiichi Sankyo Europe GmbH
E-mail: service@daiichi-sankyo.eu
Tel.: +49 8978080 |
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|